Improved antifibrotic effect of a combination of verapamil and silymarin in rat-induced liver fibrosis

Arab Journal of Gastroenterology

Volumn 12, Issue 3, 2011, Pages 143-149

  Shafik, Amani N ^a   Khodeir, Mostafa M ^a   Gouda, Nadia A ^a   Mahmoud, Mohamed E ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Hepatic stellate cells; Liver fibrosis; Silymarin; Verapamil

Indexed keywords

ALANINE AMINOTRANSFERASE; LIVAMARIN; SILYMARIN; UNCLASSIFIED DRUG; VERAPAMIL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; IMMUNOHISTOCHEMISTRY; LIVER FIBROSIS; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ALANINE TRANSAMINASE; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; RATS; SILYMARIN; SWINE; TREATMENT OUTCOME; VERAPAMIL;

EID: 80455173913     PISSN: 16871979     EISSN: 20902387     Source Type: Journal    
DOI: 10.1016/j.ajg.2011.07.001     Document Type: Article

References (48)

1. Iredale J.P. Cirrhosis: new research provides a basis for rational and targeted treatments. BMJ 2003, 327:143-147.
2. Pinzani M., Rombouts K. Liver fibrosis: from the bench to clinical targets. Dig Liver Dis 2004, 36:231-242.
3. Marina B., Martín P., Antonio P., et al. Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. Liver Transpl 2003, 9:228-235.
4. Bataller R., Brenner D.A. Liver fibrosis. J Clin Invest 2005, 115:209-218.
5. Reynaert H., Thompson M.G., Thomas T., Geerts A. Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut 2002, 50:571-581.
6. Gabele E., Brenner D.A., Rippe R.A. Liver fibrosis: signals leading to the amplification of the fibrogenic hepatic stellate cell. Front Biosci 2003, 8:69-77.
7. Sato M., Suzuki S., Senoo H. Hepatic stellate cells: unique characteristics in cell biology and phenotype. Cell Struct Funct 2003, 28:105-112.
8. Gines P., Cardenas A., Arroyo V., Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004, 350:1646-1654.
9. Maier K.P. Drug therapy in chronic liver disease. Schweiz Rundsch Med Prax 2005, 94:1907-1912.
10. Bataller R., Brenner D.A. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis 2001, 21:437-451.
11. Bellomo G., Fulceri R., Albano E., et al. Ca(2+)-dependent and independent mitochondrial damage in hepatocellular injury. Cell Calcium 1991, 12(5):335-341.
12. 2+ channels. J Physiol 2001, 535:663-677.
13. Francine R. Milk Thistle. Am Fam Physician 2005, 72:1285-1288.
14. Ferenci P., Dragosics B., Dittrich H., et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989, 9:105-113.
15. Dehmlow C., Erhard J., De Groot H. Inhibition of kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 1996, 23:749-754.
16. De La Puerta R., Martinez E., Bravo L., Ahumada M.C. Effect of silymarin on different acute inflammation models and on leukocyte migration. J Pharm Pharmacol 1996, 48:968-970.
17. Luper S. A review of plants used in the treatment of liver disease: part I. Altern Med Rev 1998, 3:410-421.
18. Paronetto F., Popper H. Chronic liver injury induced by immunologic reactions Cirrhosis following immunization with heterologous sera. Am J Pathol 1966, 49:1087-1101.
19. Vollmar B., Siegmund S., Richter S., Menger M.D. Microvascular consequences of Kupffer cell modulation in rat liver fibrogenesis. J Pathol 1999, 189:85-91.
20. Xu D., Wu Y., Liao Z.X., Wang H. Protective effect of verapamil on multiple hepatotoxic factors-induced liver fibrosis in rats. Pharmacol Res 2007, 55:280-286.
21. Reitman S., Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol 1957, 28:56-63.
22. Andrade R.G., Gotardo B.M., Assis B.C., Mengel J., Andrade Z.A. Immunological tolerance to Pig-serum partially inhibits the formation of septal fibrosis of the liver in capillaria hepatica infected rats laboratorio de patologia experi. Mem Inst Oswaldo Cruz, Rio de Janeiro 2004, 99:703-707.
23. Ishak K., Baptista A., Bianchi L., et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22:696-699.
24. Boigk G., Stroedter L., Herbst H., Waldschmidt J., Riecken E.O., Schuppan D. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 1997, 26:643-649.
25. Boenisch T, Farmilo A, Stead R. staining methods in: immunohistochemical staining methods, 3rd ed., Carpinteria, Dakocytomation corporation 2001: 26-31.
26. Lu L.G., Zeng M.D., Li J.Q., et al. Effect of arachidonic acid and linoleic acid on proliferation of rat hepatic stellate cells. Shijie Huaren Xiaohua Zazhi 1999, 7:10-12.
27. Albanis E., Friedman S.L. Hepatic fibrosis. Pathogenesis and principles of therapy. Clin Liver Dis 2001, 5:315-334.
28. Wasser S., Tan C.E. Experimental models of hepatic fibrosis in the rat. Ann Acad Med Singapore 1999, 28:109-111.
29. Rojkind M., Greenwel P. Animal models of liver fibrosis. Adv Vet Sci Comp Med 1993, 37:333-355.
30. Wu X.N. Update therapy of chronic hepatitis B in China: recent progress China Nati. J New Gastroenterol 1996, 2:65-68.
31. Chun-Song Wu, Xi-Xu Piao, Dong-Ming Piao, Yong-Ri Jin, Cheng-Hao Li Treatment of pig serum-induced rat liver fibrosis with Boschniakia rossica, oxymatrine and interferon-α. World J Gastroenterol 2005, 11(1):122-126.
32. Dan Xu, Yong Wu, Zhang-Xiu Liao, Hui Wang Protective effect of verapamil on multiple hepatotoxic factors-induced liver fibrosis in rats. Pharmacol Res 2007, 55(4):280-286.
33. Zilton A., Andrade A.G. Influence of the route of administration of Pig-serum in the induction of hepatic septal fibrosis in rats. Mem Inst Oswaldo Cruz, Rio de Janeiro 1996, 91:769.
34. Burdin N., Brossay L., Kronenberg M. Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur J Immunol 1999, 29:2014-2025.
35. Takeda K., Hayakawa Y., Van Kaer L., Matsuda H., Yagita H., Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Nat Acad Sci USA 2000, 97:5498-5503.
36. Yoshiji H., Kuriyama S., Yoshii J., et al. Angiotensin II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001, 34:745-750.
37. Don C.R. Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol (AGA) 2005, 95-107.
38. Wang J., Li D.G., Lu H.M., et al. Effect of low density lipoprotein and calcium antagonists on fat storing cells in rat. Shijie Huaren Xiaohua Zazhi 1999, 7:57-59.
39. Oide H., Thurman R.G. Hepatic ito cells contain calcium channels: increases with transforming growth factor-beta 1. Hepatology 1994, 20:1009-1014.
40. Bataller R., Gasull X., Ginès P., et al. In vitro and in vivo activation of rat hepatic stellate cells results in de novo expression of L-type voltage-operated calcium channels. Hepatology 2001, 33:956-962.
41. Toshio N., Shigeki A., Kazunobu M., et al. Expression of the Na+/Ca2+ exchanger emerges in hepatic stellate cells after activation in association with liver fibrosis. Proc Natl Acad Sci USA 1998, 95:5389-5494.
42. 2+ and rho signaling pathways: two paths to hepatic stellate cell contraction. Hepatology 2001, 4:1007-1008.
43. Fuchs E.C., Weyhenmeyer R., Weiner O.H. Effects of silibinin and of a synthetic analogue on isolated rat hepatic stellate cells and myofibroblasts. Arzneimittelforschung 1997, 47:1383-1387.
44. Zi X., Agarwal R. Modulation of mitogen-activated protein kinase activation and cell cycle regulators by the potent skin cancer preventive agent silymarin. Biochem Biophys Res Commun 1999, 263:528-536.
45. Jia J.D., Bauer M., Cho J.J., et al. Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1. J Hepatol 2001, 35:392-398.
46. Gabriele B., Hermann H., Ji-Dong J., Ernst O.R., Detlef S. Effect of antifibrotic agent silymarin on liver cell regeneration in a rat model of secondary biliary fibrosis: a morphometric analysis. Phytother Res 1998, 12(S1):42-44.
47. Shravan Y.K., Ramesh G., Adukondalu D., et al. Effect of silymarin and pomegranate pretreatment on intestinal transport of buspirone across rat intestine. Acta Pharm Sci 2009, 51:289-296.
48. Jhy-Wen W., Lie-Chwen L., Tung-Hu T. Drug-drug interactions of silymarin on the perspective of pharmacokinetics. Review article. J Ethnopharmacol 2009, 121(2, 21):185-193.